Best overall response to PI3Kδ inhibitor INCB040093 alone or in combination with JAK1 inhibitor itacitinib, by lymphoma subtype (ITT)
| . | Monotherapy (n = 49) . | Combination therapy (n = 72) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Response category . | cHL (n = 17) . | CLL/SLL (n = 12) . | FL (n = 8) . | MCL (n = 6) . | Other* (n = 6) . | DLBCL (n = 23) . | cHL (n = 21) . | FL (n = 11) . | Transformed NHL (n = 8) . | Other† (n = 9) . |
| ORR, n (%) (95% CI) | 5 (29) (10-56) | 6 (50) (21-79) | 5 (63) (24-91) | 2 (33) (4-78) | 3 (50) (12-88) | 6 (26) (10-48) | 14 (67) (43-85) | 4 (36) (11-69) | 1 (13) (0-53) | 3 (33) (7-70) |
| CR, n (%) | 2 (12) | 0 | 1 (13) | 1 (17) | 0 | 4 (17) | 8 (38) | 1 (9) | 1 (13) | 0 |
| PR, n (%) | 3 (18) | 6 (50) | 4 (50) | 1 (17) | 3 (50) | 2 (9) | 6 (29) | 3 (27) | 0 | 3 (33) |
| SD, n (%) | 6 (35) | 4 (33) | 2 (25) | 3 (50) | 1 (17) | 3 (13) | 2 (10) | 3 (27) | 0 | 4 (44)‡ |
| PD,¶ n (%) | 6 (35) | 0 | 0 | 1 (17) | 1 (17) | 10 (43) | 4 (19) | 2 (18) | 6 (75) | 1 (11) |
| Not assessed/not evaluable,§ n (%) | 0 | 2 (17) | 1 (13) | 0 | 1 (17) | 4 (17) | 1 (5) | 2 (18) | 1 (13) | 1 (11) |
| . | Monotherapy (n = 49) . | Combination therapy (n = 72) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Response category . | cHL (n = 17) . | CLL/SLL (n = 12) . | FL (n = 8) . | MCL (n = 6) . | Other* (n = 6) . | DLBCL (n = 23) . | cHL (n = 21) . | FL (n = 11) . | Transformed NHL (n = 8) . | Other† (n = 9) . |
| ORR, n (%) (95% CI) | 5 (29) (10-56) | 6 (50) (21-79) | 5 (63) (24-91) | 2 (33) (4-78) | 3 (50) (12-88) | 6 (26) (10-48) | 14 (67) (43-85) | 4 (36) (11-69) | 1 (13) (0-53) | 3 (33) (7-70) |
| CR, n (%) | 2 (12) | 0 | 1 (13) | 1 (17) | 0 | 4 (17) | 8 (38) | 1 (9) | 1 (13) | 0 |
| PR, n (%) | 3 (18) | 6 (50) | 4 (50) | 1 (17) | 3 (50) | 2 (9) | 6 (29) | 3 (27) | 0 | 3 (33) |
| SD, n (%) | 6 (35) | 4 (33) | 2 (25) | 3 (50) | 1 (17) | 3 (13) | 2 (10) | 3 (27) | 0 | 4 (44)‡ |
| PD,¶ n (%) | 6 (35) | 0 | 0 | 1 (17) | 1 (17) | 10 (43) | 4 (19) | 2 (18) | 6 (75) | 1 (11) |
| Not assessed/not evaluable,§ n (%) | 0 | 2 (17) | 1 (13) | 0 | 1 (17) | 4 (17) | 1 (5) | 2 (18) | 1 (13) | 1 (11) |
CLL assessed according to Hallek et al21 and Cheson et al22 ; WM assessed according to Owen et al24 ; all other lymphoma subtypes assessed according to Cheson et al.23
PD, progressive disease; SD, stable disease.
DLBCL (n = 2), WM, nodal MZL, splenic MZL, and transformed NHL (n = 1 each).
WM, PMBCL, splenic MZL (n = 2 each), nodal MZL, CLL/SLL, and NLP HL (n = 1 each).
Four patients had SD, including 1 patient with WM who had a minor response, which was not considered a response per protocol.
PD includes relapsed disease (after CR) or PD.
Includes patients without a follow-up response assessment or response assessment that was not evaluable.